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Abstract
Fetal growth restriction (FGR) affects 3–5%
of pregnancies and is associated with increased
perinatal morbidity and mortality. Currently,
there is no reliable biochemical test to differen-
tiate a pathological FGR from a nonpathologi-
cal one. The objective of this study was to
screen whole maternal plasma to identify dif-
ferentially expressed relatively abundant pro-
teins associated with FGR. We analyzed
maternal plasma from FGR (n = 28) and healthy
(n = 22) pregnancies using two-dimensional gel
electrophoresis (2D-GE) followed by software
image analysis. Three spots with molecular
weight (Mr) 18 kDa corresponding to hap-
toglobin (hp) α2, as identified by LC-MS/MS
and immunoblotting, showed differential
expression patterns in FGR. The distribution of
hp α2 variants in maternal plasma samples
showed the hp α2 variant 1 was low in 72% of
FGR, medium in 16%, whereas high in 12%. In
comparison, hp α2 variant 1 was high in (41%)
of controls, medium in 41%, and low in 18% of
cases. Based on the software image analysis, the
mean spot volume for hp α2 variant 1 was 0.12
(SD = 0.18) for FGR compared to 0.26 (SD =
0.19) for control (p = 0.006). Given that hp
turnover is indicative of its maturation process
and is traceable in plasma by its dominant/
suppressed variants, we propose that hp α2 is
an important potential target for evaluation of
its clinical and pathophysiological role and as
a diagnostic biomarker in FGR.
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Introduction
Fetal growth restriction (FGR) is a preg-
nancy condition where estimated fetal weight
is below the 10th percentile expected for gesta-
tional age (GA) (1,2). The condition affects
3–5% of pregnancies, and is associated with
high perinatal morbidity and mortality (3).
FGR infants may also have an increased risk of
adverse neurodevelopmental outcomes and of
cardiovascular and metabolic diseases later in
life (4,5). Currently, fetal size is routinely ascer-
tained using imaging technology; however, the
differentiation of normal, constitutionally small
fetuses from those with pathologic FGR
remains a clinical challenge. Identification of
proteins that can be used as biomarkers is an
antecedent step in the development of non-
invasive diagnostic or prognostic tests for FGR.
Discovery of a candidate biomarker protein or
a group of proteins that are associated with the
pathophysiology of FGR, should lead to the
development of rapid detection and quantifi-
cation methods, for example immunoassays
(6,7), for possible clinical screening. The mea-
surement of biomarkers combined with
advanced ultrasonographic (US) biometry and
fetal Doppler technology in a temporal manner
will provide the ability to more accurately and
precisely detect the presence of FGR.
Clinically significant FGR is caused by
reduced fetal growth resulting from maternal
conditions such as undernutrition, smoking,
drugs, and prepregnancy or pregnancy dis-
eases, that include chronic hypertension or
preeclampsia (8). Although the etiology and
pathophysiology of FGR may be varied (2), 
it is widely accepted that poor placental
development and or placental disease is the
major common factor that is associated with
abnormal fetal growth (8,9). Once congenital
infection and chromosomal or congenital
anomalies have been ruled out, FGR is mostly
a result of uteroplacental insufficiency (10).
Proteomic analysis of maternal plasma may
also provide us with better understanding of
the pathophysiology underlying FGR.
Profiles of plasma proteins can illustrate
changes owing to altered metabolism and/or
disease process. They may have a causal rela-
tionship and/or indicate disease severity. Dif-
ferential expression of proteins in blood
plasma has been widely used to study various
diseases (11–13). The significance of several
plasma peptides in gestational diseases with
respect to biomarker discovery, and the impor-
tance of proteomics in identifying these candi-
date proteins have been well denoted (14).
Analysis of global plasma proteins is a chal-
lenge because of the complexity of plasma
proteome’s large dynamic range, chemical
similarity of multiple protein species and in
addition presence of major plasma proteins
such as albumin and γ globulin. To overcome
these difficulties, prefractionation and deple-
tion is often employed to adequately quantify
detectable spots. Because these strategies
often lead to high variability, this study is
focused on rapid screening of whole plasma
using two-dimensional gel electrophoresis
(2D-GE) as a proteomic approach to detect




All chemicals for 2D-GE and LC-MS/MS
analysis were of electrophoretic or analytical
grade. The total plasma protein concentrations
were measured using BCA Protein Assay Kit
(Pierce Biotech Inc., Rockford, IL), following
the microplate technique as outlined by the
manufacturer. BSA was used as the standard.
Replicates were analyzed in a Multiskan EX
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microplate reader (Thermo Electron Corp.,
Vantaa, Finland).
Subjects
With approval from the University of West-
ern Ontario, Health Sciences Research Ethics
Board (HSREB) and written informed consent
from participants, pregnant women were
recruited at St. Joseph’s Hospital, London, ON,
Canada. Blood samples were collected prior
to delivery from mothers who consented to
participate in the study. Table 1A shows a
summary of the characteristics of the patients
studied, and the inclusion and exclusion cri-
teria for subject recruitment. Gestational age
(GA) was determined by certain last men-
strual date of mothers or the first trimester US
crown rump length. Congenital infection and
chromosomal or congenital anomalies were
ruled out. Clinical information abstracted
from the antenatal records included standard
tests for the evaluation of fetal health and risk
factors as part of normal surveillance. The
diagnosis of FGR group was based on last
trimester estimated fetal weight as deter-
mined by fetal US biometry (15) and calcu-
lated using the Hadlock II formula. Birth
weight percentiles were calculated based on
their respective gender and GA using a stan-
dardized growth chart (16,17). Control group
subjects consist of normal pregnancies with-
out medical or obstetric problems and with
fetuses within normal growth percentiles
(>25th). Measurements less than the 10th per-
centile for GA at birth were confirmed to be
growth restricted (Table 1B). Placental insuf-
ficiency was determined by abnormal umbili-
cal artery Doppler (18).
Maternal Plasma Samples
One to two milliliters of maternal venous
blood from FGR and control subjects were col-
lected in EDTA coated tubes. Blood was cen-
trifuged (2000g, 10 min at 4°C) and plasma
samples were saved in small aliquots at –70°C
until analysis.
SDS Polyacrylamide Gel Electrophoresis
(1D- and 2D-GE)
All protein separations on 1D and 2D gels
were conducted using 1.5 mm 12% SDS
polyacrylamide gels, run for 20 min at 80 V
followed by approx 1 h 15 min at 120 V.
Prestained Broad Range SDS molecular weight
(Mr) marker (Bio-Rad Labs, Hercules, CA) was
used for estimation of Mr. All relevant
reagents for 2D-GE were purchased from
Bio-Rad and used according to manufacturer’s
instructions.
First Dimension Isoelectric Focusing for 2D-GE
The isoelectric focusing (IEF) was performed
using PROTEAN IEF cell with ReadyStrip
immobilized pH gradient (IPG) strips, 7 cm,
pH 3.0–10.0 nonlinear (NL), unless otherwise
specified. For first dimension separation,
maternal plasma (1.5 µL, ~90 µg protein) was
made up to 125 µL with rehydration buffer 
(8 M urea, 2% CHAPS, 50 mM dithiothreitol
[DTT], 0.2% Biolyte pH 3.0–10.0 ampholyte,
0.001% bromophenol blue). Prior to IEF, IPG
strips were rehydrated overnight using active
or passive rehydration. Proteins were sepa-
rated using a programmed voltage gradient in
steps; S1, 200 V, 100 Vh; S2, 500 V, 250 Vh; 
S3, 1000 V, 500 Vh; S4, 8000 V, 8000 Vh; S5
500 V (holding step), with rapid ramping and
a maximum current of 50 µA/strip through-
out. Electrofocused strips were stored at –80°C
until used.
Second Dimension Separation for 2D-GE
Focused strips were incubated for 20 min in
2.5 mL equilibration buffer (Tris, pH 8.8 
[50 mM], urea [6 M], SDS [2% w/v], and glyc-
erol [30% v/v] containing DTT [1% w/v]), fol-
lowed by another 20 min incubation with 2.5 mL
equilibration buffer containing iodoacetamide 
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(2.5% w/v). The IPG strips were placed on the
second dimensional gel using 0.5% low melt-
ing gel agarose in 1X Tris glycine SDS buffer
with 0.003% bromophenol blue. Electrophore-
sis was performed on SDS gels with a narrow
(7%) stacking gel. Fixation was for 30 min (10%
methanol and 7% acetic acid) followed by
staining overnight with SYPRO Ruby gel stain
(Bio-Rad). Destaining was done for a mini-
mum of 1.5 h using 10% methanol and 7%
acetic acid solution.
Two D-GE Image Processing
The 2D gels were stained with SYPRO Ruby
Red and the monochromatic 16-bit digital
images were acquired using the Fluorochem
8800 imaging system (Alpha Innotech Corp.
San Leandro, CA) employing ultraviolet light
excitation with a SYPRO-500 filter integrated
with imaging software. Acquisition of all
images was performed under controlled con-
ditions with consistent exposure times.
Phoretix 2D Expression Software Analysis
Phoretix 2D Expression 2005 software
(Nonlinear Dynamics Ltd., Newcastle Upon
Tyne, UK) was used for image analysis of 2D
gels using normalization of the spots on
replicate gels. Preliminary mapping of
plasma protein spots on 2D gels was per-
formed based on the published plasma map
(SWISS 2D-GE database available at the
Table 1A
Study Group Characteristics
Subject characteristicsa FGR Normal pregnancy p-value
Total study subjects n = 28 n = 22
Abnormal Doppler n = 15
Normal Doppler n = 7
No Doppler n = 6
Mean maternal age
(range 18 to 37 yr) 25.8 yr (SD = 6.2) 25.9 yr (SD = 4.6) 0.96
GA (range 23 to 40 wk) >28 wk 25 (89.2%) 15 (68%) 0.084
≤28 wk 3 (10.7%) 7 (31.8%)
Mean placental weight (g) 28–36 wk 336.7 (SD = 40.9) 489.18 (SD = 137.1) 0.006
Mode of delivery Vaginal 14 (50%) 16 (72.7%) 0.1
Caesarian section 14 (50%) 6 (27.3%)
Gender of newborn Male 13 (46.4%) 18 (81.8%) 0.01
Female 15 (53.6%) 4 (18.2%)
Table 1B
Distribution of Percentile of the Newborn Based on Gestational Age in FGR Group
FGR Newborn percentile <28 wk GA (n) >28 wk GA (n)
<5th 1 6
5th–10th 3 18
aInclusion and exclusion criteria: Singleton pregnancies with growth restricted fetus in North American pop-
ulation were included. The subjects with twins, premature ruptured membranes, abruption placenta, fetal con-
genital or genetic abnormalities, diabetes, thyroid disorder and chronic hypertensive disorders, chorioamnionitis,
preeclampsia smokers, drug users, and subjects with malnutrition were excluded.
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ExPASy (Expert Protein Analysis System)
website (http://ca.expasy.org/ch2d).
Protein Identification Using LC-MS/MS
Peptide Sample Preparation
Specific spots containing proteins of inter-
est were picked and manually excised for in-
gel digestion. In brief, excised gel spots were
transferred to siliconized tubes, destained, and
washed. Proteins were reduced, alkylated, and
then digested with sequencing grade trypsin
(Promega, Madison, WI) overnight at 37°C.
After extraction of peptides from the gel, the
samples were dried in a vacuum centrifuge
and dissolved in 0.2% formic acid ready for
LC-MS/MS analysis.
LC-MS/MS
LC-MS/MS analysis was carried out on a
Q-TOF Global Ultima mass spectrometer
(Waters Micromass® MS; Waters Corp., Mil-
ford, MA) coupled with a Waters CapLC. The
LC system consisted of a C18 analytical
column (75 µm × 15 cm, 5 µm, LC Packings,
Amsterdam, the Netherlands) and nano-ESI
source. For the standard LC-MS/MS proce-
dure, a gradient (solvent A, 0.2% formic acid
in water, B, 0.2% formic acid in acetonotrile,
5% B to 90% B in 60 min) was used to elute
the peptides. The data-dependent acquisition
function was used to both detect and sequen-
tially perform collision-induced dissociation
(CID) on the multiply charged ions that satis-
fied the selection criteria. The mass spectrom-
eter was operated in positive-ion mode with
MS data acquisition range, 300 to 1900 and
MS/MS data acquisition range, 50 to 1900. The
collision energy (CE) for MS/MS experiments
was determined by the charge state and/or by
the m/z range of the precursor ion. The CE
values were according to standard charge-
state recognition and CE files recommended
by Micromass (Waters Corp.). The MS to
MS/MS switching was allowed for the four
most abundant precursors in the survey
experiment with a 30-s time period set for
MS/MS data acquisition for each peptide. In
some cases, a precise list of peptides was set
so that specific precursor ions were targeted to
undergo tandem MS preferentially. For the MS
and MS/MS experiments, the time-of-flight
(TOF) instrument was calibrated with an
MS/MS spectrum of Glu-fibrinopeptide-b.
Data were acquired using MassLynx 4.0 soft-
ware (Waters Corp.).
Analysis of MS/MS Data
Data was further analyzed using MassLynx
4.0 software (Waters Corp.) and Mascot (19) for
database search on Swiss-Prot. The mass toler-
ance for precursor and fragment ions was set to
1.2 and 0.1 Da, respectively. Carbamidomethy-
lated cysteine residue was set as a variable
modification. All identified peptides during
Mascot or Peaks (Bioinformatics Solutions Inc.
Waterloo, Canada) searching were verified by
manual interpretation of the spectra.
Identification and Qualitative Evaluation
of hp Variants by 2D Western
Immunoblot Analysis
The identity of hp subtypes/subunits (α1,
α2, and β) and qualitative assessment of their
expression in select plasma samples was per-
formed by 2D Western immunoblot analysis.
An equal volume of maternal plasma (~45 µg
protein) from a severe case of FGR and a GA
matched control subject were compared using
7-cm IPG strips, pH 4.0–7.0 for 2D-GE. Pro-
teins separated on the gels were transferred
onto a PVDF membrane (0.45 µm) (Hoffmann-
La Roche Ltd., Basel, Switzerland) using a
semi-dry Transblot apparatus (Bio-Rad). The
membrane was blocked with 5% non-fat dry
milk in TBS (50 mM Tris, pH 7.5, 150 mM
NaCl) for 2 h at room temperature, followed
by incubation with the primary polyclonal
rabbit anti-human hp antibody that recognizes
all hp subtypes (Dako, Glostrup, Denmark)
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(1:5000 in TBS containing 1% non-fat dry milk
and 0.1% Tween-20) at 4°C for 3 h. Anti-rabbit
IgG was used as a secondary antibody in 1:8000
dilution (TBS containing 5% non-fat dry milk)
at room temperature for 1 h. The blot was rinsed
in TBS containing 0.5% Tween-20, and proteins
were visualized using ECL Western Blotting
Detection System (GE Healthcare, Piscataway,
NJ) according to manufacturer’s instructions.
Identification and Semiquantitative 
Evaluation of hp Subtypes Using 1D
Western Immunoblot Analysis
One-dimensional Western immunoblot anal-
ysis of maternal plasma was performed on five
representative samples from FGR and three
from the control group. The FGR subjects were
the most severe cases with <3rd percentile
newborn birth weight for GA, whereas con-
trols were of appropriate for gestational age.
The dilutions of the polyclonal rabbit, anti-
human hp antibody (Dako) and the conditions
for immunoblotting were the same as described
earlier for 2D immunoblots. The plasma samples
in equal volumes (~5 µg protein) were pre-
treated with 2-mercaptoethanol (final concen-
tration 1%) and subjected to 1D-GE. The
immunoblot consisted of 0.1 µg standard
purified hp (GE Healthcare) as a reference/
positive control. Optical densitometric analysis
of bands corresponding to the three hp subtypes
(α1, α2, and β) in respective bands on the 1D
immunoblot was performed using Phoretix 1D
software. The background subtraction, selection
of lanes analyzed and the detection of specific
bands for software quantification were all done
manually. The quantification of 1D immunoblots
was performed by densitometry using Phoretix
1D advanced v5.10 software (Nonlinear
Dynamics Ltd.).
Two D-GE Image Pocessing and Phoretix
2D Expression Software Analysis
For quantification of intensities of the spots
on 2D gels for the specified proteins, Phoretix
2D expression software was used to analyze
replicate gels under identical conditions. The
software includes automated spot detection,
gel matching, background correction, and data
normalization. For analysis in this study how-
ever, spots of interest were manually matched
because of the complexity of the gel images.
The background intensity for individual spots
was based on the intensity in a radius that
extended 45 pixels in all directions (mode of
non-spot). The spot volume was denoted by
the sum pixel intensity within a spot minus
the background. Individual spot volumes
were divided by the sum total of all spot vol-
umes on a particular gel and multiplied by a
constant (100). “Normalization of spot vol-
umes” was carried out to correct for random
error as well as inherent total protein varia-
tion, and was used for statistical comparison.
Statistical Analysis
Chi-square test was used to compare cate-
gorical variables between the FGR and control
groups, or the Fisher’s exact test where appro-
priate. The independent samples t-test was
used to compare mean differences in continu-
ous variables between the two groups. The
Pearson correlation coefficient assessed the
relationship between two continuous variables
and scatter plots were produced to test for lin-
earity. Statistical significance was determined
at p ≤ 0.05. Because the sample sizes based on
GA grouping described in Table 1A were low
in the respective groups, and the observations
in each group did not follow a normal distri-
bution, we employed a nonparametric proce-
dure using the Mann-Whitney test.
Results
Clinical Data
The clinical characteristics of the subjects 
in this study are described in Table 1A,B.
Pregnancies were categorized into two groups
namely <28 wk or ≥28 wk gestation. The
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controls were of appropriate for GA. Based on
the uterine artery Doppler velocimetry >50%
of subjects were diagnosed with placental
insufficiency, and the majority were in the ≥28
wk GA group. The placental weights of FGR
pregnancies (336.7 ± 40.9 g) were significantly
lower than those of controls (489.2 ± 137.1 g)
(p = 0.006).
Proteomic Analysis of Maternal Plasma
From FGR and Normal Pregnancies
Using 2D-GE
Initial evaluative studies showed that IEF
with active rehydration provided a better res-
olution of proteins as compared to passive
rehydration (data not shown). In addition, an
improved resolution of proteins was attained
on the 2D gels using IPG strips, pH 3.0–10.0
NL compared to linear that is currently not
depicted. All subsequent 2D-GE analyses were
thus performed using IPG strips pH 3.0–10.0
NL. A representative comparison of protein
spots on 2D-GE maps of maternal plasma
from GA matched FGR and control subjects is
shown in Fig. 1A (i) and (ii), respectively.
Although IPG strips, pH 3.0–10.0 NL provided
better resolution of plasma proteins, the 7-cm
strips did not optimally separate all abundant
plasma proteins, specifically, in the higher Mr
range. High abundant proteins, such as albu-
min and IgG, obscured the identification and
quantification of minor proteins in and around
this zone. The current protocol however,
allowed successful discrimination of protein
quantities between control and FGR samples,
specifically in the lower Mr region. Only well-
separated and defined spots on the 2D gel
images, quantifiable by software analysis,
were further characterized. From the gel
images, a set of five major visible spots in the
lower Mr range, were prominent, labeled as
1–5 (Fig. 1 [ii]). Comparison with the plasma
map (EXPASY) indicated spots 1–3 as hp α2
chain variants, spot 4 as transthyretin (TTR),
and spot 5 as retinol binding protein (RBP).
The hp α2 in plasma from FGR pregnancies
showed three different patterns of expression.
In the first pattern, hp spots 1, 2, and 3 were
near to, or below, the threshold of detection,
as shown in Fig. 1B (i), that was seen in 29%
of FGR pregnancies. This pattern in controls
was detected in 33% of pregnancies. In the
second pattern, all three hp spots (1, 2, and 3)
were of relatively high intensity, as shown in
Fig. 1B (ii), was most commonly observed in
controls (52% of pregnancies) and present in
only in a small number (13%) of FGR preg-
nancies. In the third pattern, only spot 1 was
reduced in intensity, as shown in Fig. 1B (iii),
was most prevalent (67%) in the FGR preg-
nancies, and was not commonly seen in the
controls (14% of pregnancies).
Shown in Fig. 1C is the correlation of the
same protein between two gels run under
identical conditions. The R-squared for the
linear plot was 0.86 suggesting relatively low
intergel variability.
Identification of Proteins
The identities of spots 1, 2, and 3 as variants
of hp α2 chain, and spot 4 as TTR were made
by LC MS/MS followed by Mascot searches
(Table 2). Although a low coverage (3–11%) for
hp α2 variants and (28%) for TTR were
obtained, the high quality of MS/MS spectra
(Fig. 2) established the identity of these proteins
in the select spots. No significant hits for other
proteins were found in the region of these spots.
Hp α2 variant proteins identified by MS
were confirmed by 2D immunoblot analysis
(Fig. 3A [i]). Plasma from FGR and control sub-
ject showed variable intensities of protein
species with Mr 16, 18, and 42 kDa, correspond-
ing to α chains (α1 and α2) and a β chain of hp,
respectively (Fig. 3A [i, ii]). Both hp α1 and α2
variants were reduced significantly in FGR
(Fig. 3A [i]) compared to controls (Fig. 3A [ii]).
Immunoblotting corroborated the 2D-GE data
with SYPRO Ruby stained gels (Fig. 1A [i, ii]).
Additional spots (a, b, and c) were detected
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Fig. 1. (A) Representation of comparison of 2D-GE maps using maternal plasma from FGR (i) and control (ii)
subjects with matched GA. For FGR gels (i) spots 1, 2, and 3 (hp α2 variants) were absent as compared with
the control (ii). Spot 4 (TTR) was moderately increased in FGR subjects while spot 5 (RBP) showed no
detectable change in its expression. (B) A magnified, maximally contrasted three-dimensional rendering of 2D
images for spots 1–5.The three different patterns primarily observed are represented (B [i, ii, and iii]). (C)
Comparison of matched spots with normalized volumes detected on two 2D-GE maps of an identical maternal
plasma sample prepared on separate occasions.The R squared for the trend-line was 0.86.
compared to 2D-GE. As shown in Fig, 3A (ii),
spot (a) corresponded to the fourth variant of
hp α2, whereas spots (b) and (c) corresponded
to two extra variants of hp α1 in the control
plasma. The additional spots (a), (b), and (c)
seen in the controls were absent in the FGR.
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Semiquantitative Evaluation of hp 
Variants Using 1D Immunoblotting
The specificity of the polyclonal antibody
provided additional information on all hp
subtypes. The analysis of plasma samples
from FGR and control subjects (Fig. 3B) using
anti-human hp antibody showed variable
intensities of three bands with Mr 16, 18, and
42, corresponding to hp α1, α2, and β sub-
types, respectively (Fig. 3B, lanes 1–8). The hp
standard purified from pooled human plasma
shown in lane 9 (Fig. 3B) as a positive control,
exhibited high intensity of 18 and 42 kDa
bands but a fainter band at 16 kDa.
Of the five samples representing the mater-
nal plasma from FGR subjects in this study,
three revealed hp α2 to be absent in FGR (Fig.
3B; lanes 2, 3, and 5). The band corresponding
to hp α1 however, was absent in two out of
five FGR samples (Fig. 3B; lane 1 and 4),
whereas the intensity of this variant was rela-
tively reduced in the remaining three samples
(Fig. 3B; lanes 2, 3, and 5). Although the rep-
resentative samples from controls (lanes 6–8)
showed varied signals, the intensities for both
hp α2 and hp α1 bands were relatively higher
than the FGR group. Quantitation of mean hp
band intensity using optical densitometry led
to determine the reduction in hp. A 25.6%
reduction was observed for hp β, 31.3% for hp
α1 and 93.0% for hp α2 subtypes in FGR com-
pared to the control. The data demonstrated a
Table 2
Summary of Software Spot Quantation of 2-D Gels and MS/MS Identification on Specific Protein Spots
From Maternal Plasma From FGR and Control Pregnancies.
*not identified.
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moderate or inconclusive reduction of hp β
and hp α1 expression, nonetheless, a distinct
reduction in hp α2 in FGR.
Image Analysis Quantification 
of hp α2 Variants
Statistical evaluation of normalized spot
volumes for spots 1–3, (hp α2 variants 1 to 3),
spot 4 (TTR), and spot 5 (RBP) on 2D gels as
represented in Fig. 1A (i, ii) in FGR and
control subjects is shown in Table 2. We used
RBP as a quantitative control for a better indi-
cation of validity of evaluation of spots on the
gels. The mean spot intensity for hp variant 1
was significantly reduced in FGR compared 
to controls (p = 0.006), whereas TTR was
higher in FGR compared to controls (p = 0.001).
To further analyze the distribution of hp vari-
ant 1 between control and FGR, the distribu-
tion of normalized volumes was plotted based
on their z score, low (<0), medium (0–1 to 1)
and high (normal) (>1). Figure 4 illustrates the
intensity of hp α2 variant 1 to be high or
medium in the majority (59%) of controls, in
comparison to only 28% of FGR subjects. As
shown in Fig. 4, the distribution of hp α2 vari-
ant 1 volumes for FGR were negatively skewed,
with 72% of hp α2 variant 1 volumes being >1
SD below the overall mean compared to 40%
in control.
Furthermore, we investigated the relationship
between uterine artery Doppler flow velocime-
try and the frequency of reduced hp α2 variant
1 in FGR accompanied by abnormal Doppler.
Hp spot 1 expressed as normalized volumes
were low to medium (53.3% with low and 27%
with medium) in 80% of FGR accompanied by
abnormal Doppler, as compared to only 20% of
FGR with normal Doppler.
Discussion
Our results suggest that 2D-GE combined
with LC-MS/MS is a feasible approach to
identify changes in relatively abundant low
molecular weight proteins in unfractionated
plasma. Although 2D-GE analysis of whole
plasma is a challenging and time consuming
approach for comprehensive protein analysis, it
allowed us to discover semiquantitative changes
in the proteome of FGR pregnancies. New pow-
erful image analysis software was crucial in the
initial identification of changes in the plasma
proteome and led us to determine that a specific
variant of hp α2 chain was reduced in the
maternal plasma of FGR, but not of controls.
FGR is associated with increased mortality
of the fetus and increased morbidity in the
neonatal period and childhood, as well as in
adulthood (4). Ultrasound fetal biometry is
used for the estimation of fetal weight in FGR
Fig. 2. LC-MS/MS spectra for the identification of the
tryptic peptides sequences of hp α2 variants and
TTR. MS/MS spectra of ion at m/z 656.31 (+2) (A)
and 720.33 (2+) (B) from spot 1, 2, and 3 corre-
sponding to hp α2; and ion at m/z 683.88 (+2) (C)
from spot 5 corresponding to TTR.
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fetuses (15–18,20), and umbilical artery Doppler
(18) is used to distinguish FGR fetuses owing
to uteroplacental insufficiency. Biophysical pro-
file assessment is also used to determine fetal
health and to provide indications for delivery.
However, these tests reflect the condition 
of the fetus at the time of assessment and do
not indicate the pathology or progression 
of the disease process that underlay FGR.
Additional tests are, therefore, necessary to
determine pathological FGR and its potential
pathophysiology.
FGR is a multifactorial disease with diverse
etiology and pathophysiology (2), thus changes
in the proteome may not be universal.
Correspondingly, to minimize heterogeneity
and the effects of confounding factors in this
study, the exclusion criteria used in the cur-
rent selection of subjects ensured requisite
health and lifestyle factors that also include
Fig. 3. (A) A comparative 2D Western immunoblot analysis using equal amount of maternal plasma protein
from a FGR (i) and a GA matched control (ii). Differentially expressed spots were detected and are identi-
fied numerically. Figure 3A (i) shows significantly reduced spots 1, 2, and 3 corresponding to hp α2 variants
as compared to the control (ii).An additional spot, denoted as (a) was detected in the control (ii) that rep-
resents the fourth variant of hp α2 (plasma map, EXPASY). Spots (b) and (c), corresponding to hp α1 vari-
ants, were only detected in the control (ii) sample. (B) Semiquantitative evaluation of hp variants in maternal
plasma using 1D immunoblot analysis. Representative maternal plasma samples from FGR (n = 5) and control
(n = 3) subjects were selected. Lane “M” consists of Mr marker. Lanes 1–5 are maternal plasma from FGR sub-
jects with low birth weight newborns (<5th percentile for GA); lanes 6–8 from the control subjects with
normal birth weight infants. Equal amount of total protein was loaded in lanes 1–8. Lane 9 consists of 0.1 µg
pure hp (Sigma) used as a positive control. Sample in lanes 4 and in 8 were common between 1D and 2D (A)
immunoblot analysis.
08_Gupta  10/19/07  7:53 AM  Page 179
Clinical Proteomics ________________________________________________________________ Volume 2, 2006
180 _______________________________________________________________________________ Gupta et al.
malnutrition. All subjects in this study were
confirmed cases of FGR and the majority of
them were a result of uteroplacental insuffi-
ciency (21). Because delivery was delayed if
intervention was not necessary (2), most of
the FGR pregnancies were ≥28 wk gestation.
Poor placental growth has been shown to limit
concurrent development of the fetus (21) and as
expected, our data shows the placental weight
of FGR pregnancies to be significantly smaller
than the matching controls. These results concur
with the significance of abnormal placental
development in FGR pregnancies (22).
Based on their relationship to growth and
development of the fetus, several peptides
have been proposed as potential biomarkers
(23). Prealbumin has been suggested to be
associated with fetal defects and pregnancy
complications (24). Leptin may reflect a
generalized response to hypoxic stimuli (25),
and free β-hCG and PAPP-A levels have been
associated with general fetal abnormality (26).
Elevated α-fetoprotein levels in the amniotic
fluid through amniocentesis have been
suggested to be of potential use in the detection
of FGR (27), however, its association with
adverse pregnancy outcome has not been con-
firmed (28). Novel biomarkers that may be more
reliable and specific in their diagnostic and prog-
nostic value in FGR remain to be identified.
Proteomic approaches offer new opportuni-
ties for potential biomarker discovery in
pregnancy disorders (14). When searching for
diagnostic markers in plasma, depleting most
abundant protein(s) may be valuable, however,
it could also lead to variability and nonspecific
protein loss (29). Although whole plasma anal-
ysis renders the possibility of detecting the
desired biomarkers challenging (30,31), it
nonetheless mitigates the complications asso-
ciated with plasma prefractionation (32). Pro-
tein expression profiling using direct MS may
be superior for identifying a larger number of
total proteins (33), however, because of the lack
of complete amino acid sequence coverage for
a protein using either MALDI-MS or LC-
MS/MS, there has been limited success in
using MS based approach to identify the iso-
form and posttranslational modification in
plasma (34). 2D gels on the other hand, gener-
ate different spots that correspond to a change
in overall protein charge and/or molecular
weight. In the current study, this technique has
allowed the identification of hp α2 as a differ-
entially expressed protein in the plasma pro-
teome, which was then confirmed by
immunoblotting. This study was feasible
because of the high abundance and adequately
separate detectable spots for hp which were
discriminated by software analysis. These
spots have previously been recognized as
structurally different species of hp α2 chain
(11,35,36). Immunoblotting revealed additional
hp α2 and hp α1 variants in the control
plasma, which has been reported previously
(35). Subsequent studies in a larger FGR popu-
lation using an immunological assay with
higher sensitivity and specificity will be crucial
in determining the clinical utility of hp α2. Hp
is a positive acute phase protein (37) that is
variably expressed in maternal plasma during
the course of pregnancy (38). Increased expres-
sion of serum hp α2 has been detected in ovar-
ian cancer and is used as a biomarker for
screening this disease (39,40). The specific
Fig. 4. Quantitative distribution of significantly differ-
ent hp α2 variant 1 expression in maternal plasma
from FGR and control subjects.
08_Gupta  10/19/07  7:53 AM  Page 180
Volume 2, 2006 ________________________________________________________________ Clinical Proteomics
Maternal Haptoglobin α2 in Fetal Growth Restriction ____________________________________________ 181
reduction in hp α2 variant, and possibly of hp
α1 protein chain, may not reflect a generalized
positive acute phase response in the FGR.
Our data is the first to demonstrate consis-
tently, the absence and/or suppression of only
a specific variant of hp α2 that migrates in the
most acidic location of the three variants as
identified on 2D gels. The differences in
isoelectric points (pI) of hp α2 variants may be
because of its posttranslational modification,
such as deamidation of asparagines (41,42).
Although the variability in intensity of hp α2
variant 1 has been linked with a carboxypep-
tidase that leads to different turnover rates of
this variant in blood (35), the pathophysiologic
basis for the suppression of specific hp vari-
ants in FGR is still unknown. The rates of
deamidation of human proteins have been
suggestive of a biologically relevant phe-
nomenon that serves as molecular timer of
biological events (43). It is possible that differ-
ences that lead to the separation or comigra-
tion of hp α2 variants in FGR may be
attributed to subtle structural modifications of
the protein that occurs during the disease 
process. The site and the cause/effect pheno-
menon for this modification in FGR is not
known, however, it is likely that the placenta
plays an important role in this process.
Changes in posttranslational processing and
not in the synthesis or secretion of hp have
been shown in colon cancer (44).
Hp is an important protein in reproduction
(45) and has been shown to be involved in the
early signaling process during preimplanta-
tion (46). Hp is present in uterus and its role in
endometrium has been suggested to be in 
protecting the fetus from a maternal allograft-
like immune response (47). Hp is involved 
in HELLP syndrome, which is linked with
hemolysis (48–50). It also suggested to be
involved in placental angiogenesis (51–53).
Because placental insufficiency is the major
common factor in FGR, it is logical to suggest
the role of hp in placental vessel remodeling.
Given the contribution of hp to placental devel-
opment (47), it will be important to determine
if hp is a marker of placental insufficiency.
Clinically relevant biomarkers may however
be of either causal or associative in nature (54).
Based on our current findings, we have initiated
a study to elucidate the mechanistic basis for hp
suppression in the pathophysiology of FGR
using human hepatoma cells as hepatic syn-
thetic machinery in vitro (55,56). Our on-going
study shows that hp biosynthesis in hepatoma
cells is altered in a similar manner by hypoxia
(unpublished data), a condition that is com-
monly associated with FGR.
In this study, we present evidence that
expression of a specific variant of hp α2, that is
a high abundance protein, is unique in FGR
patients. This is the first report in our search
toward discovery of biomarker(s) in FGR. How-
ever, for detection of larger number of plasma
proteins, specifically of low molecular weight
and low abundance, we propose to employ
our recently established prefractionation strat-
egy in a follow up study to further elucidate
the FGR proteome. Furthermore, identification
of proteins in the plasma by 2D-GE followed by
MS and the high throughput 2D LC-MS has
demonstrated that the majority of the identified
protein set was unique to each method (57)
therefore, for a comprehensive coverage, as 
suggested by Choi et al. it will be ideal to apply
the two methods to achieve optimal results for
the analysis of the plasma proteome.
The maternal blood samples in this study
were collected from pregnant women just
before delivery. The results from this study are
consistent among the subjects, who in our
assessment represent the clinical population
with the problem, and, therefore, strongly show
that we have been successful in identifying a
potential biomarker in maternal plasma indica-
tive of a late manifestation of FGR. It is recog-
nized that a differential expression does not
positively identify any protein as a biomarker
of FGR, fulfillment of other criteria such as a
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larger sample size, collection of maternal
plasma prior to birth at different gestational
ages and multifactorial analyses, will be essen-
tial before hp α2 could be used in a clinical set-
ting. The fact that the change in hp α2 correlates
with the Doppler outcomes suggests it can be a
potential diagnostic and/or prognostic marker.
If changes of hp precede the clinical diagnosis
of FGR and placental insufficiency, inclusion of
this protein in routine antenatal estimation of
fetal weight and/or umbilical artery Doppler
examination could be useful clinically.
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